Get the Stockscreener App
18.28
0.77%
0.14
Adma Biologics Inc stock is traded at $18.28, with a volume of 1.05M.
It is up +0.77% in the last 24 hours and down -10.65% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$18.14
Open:
$18.12
24h Volume:
1.05M
Relative Volume:
0.30
Market Cap:
$4.98B
Revenue:
$426.45M
Net Income/Loss:
$197.67M
P/E Ratio:
22.29
EPS:
0.82
Net Cash Flow:
$110.10M
1W Performance:
-0.65%
1M Performance:
-10.65%
6M Performance:
-0.87%
1Y Performance:
+63.07%
1-Day Range:
$17.80
$18.39
1-Week Range:
$17.67
$18.91
52-Week Range:
$10.21
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
18.28 | 4.98B | 426.45M | 197.67M | 110.10M | 0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
(ADMA) On The My Stocks Page - news.stocktradersdaily.com
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales? - sharewise
ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade) - Seeking Alpha
ADMA Biologics Stock Soars Amid Biotech Growth Nasdaq Composite Gains - Kalkine Media
The 8.3% return this week takes ADMA Biologics' (NASDAQ:ADMA) shareholders three-year gains to 964% - simplywall.st
ADMA Biologics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – ADMA - ACCESS Newswire
Adma Biologics director sells $213,100 in stock - Investing.com Australia
Adma Biologics director sells $213,100 in stock By Investing.com - Investing.com South Africa
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold? - Nasdaq
When (ADMA) Moves Investors should Listen - news.stocktradersdaily.com
adma biologics holds annual meeting, elects directors and approves proposals - Investing.com Australia
adma biologics holds annual meeting, elects directors and approves proposals By Investing.com - Investing.com South Africa
ADMA Biologics Holds Annual Stockholders Meeting - TipRanks
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - sharewise
ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com
Where are the Opportunities in (ADMA) - news.stocktradersdaily.com
Cetera Investment Advisers Decreases Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Adma Biologics director sells $182,635 in common stock - Investing.com Australia
Adma Biologics director sells $182,635 in common stock By Investing.com - Investing.com South Africa
Bank of America Corp DE Has $13.14 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Exploring High Growth Tech Stocks In The US May 2025 - Yahoo
Are Options Traders Betting on a Big Move in ADMA Biologics Stock? - The Globe and Mail
Are Options Traders Betting On A Big Move In ADMA Biologics Stock? - Barchart.com
BNP Paribas Financial Markets Sells 674,016 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Ameriprise Financial Inc. Acquires 88,542 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date - The Globe and Mail
(ADMA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
FY2025 EPS Estimates for ADMA Biologics Decreased by Analyst - Defense World
Amid Bumpy Biotech Trade, I'm Eyeing These Two Stocks - TheStreet Pro
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
ADMA Biologics (NASDAQ:ADMA) Rating Lowered to “Sell” at StockNews.com - Defense World
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates - The Globe and Mail
Revenue Gains, Bold Guidance Lift ADMA Shares - FXEmpire
Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates - MSN
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics Reports Strong Growth and Strategic Advances - TipRanks
ADMA Biologics (ADMA) Receives Price Target Upgrade from Raymond - GuruFocus
ADMA Biologics (ADMA) Receives Price Target Upgrade from Raymond James | ADMA Stock News - GuruFocus
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? - Yahoo Finance
Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits - MSN
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Adma Biologics price target raised to $32 from $25 at Raymond James - TipRanks
Raymond James Increases Price Target for ADMA Biologics | ADMA Stock News - GuruFocus
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives Propel Future Outlook - GuruFocus
Adma Biologics: Q1 Earnings Snapshot - New Haven Register
ADMA Biologics Reports Strong Q1 2025 Financial Growth - TipRanks
ADMA Biologics Inc earnings missed by $0.01, revenue topped estimates - Investing.com Nigeria
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adma Biologics Inc Stock (ADMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Jun 16 '25 |
Sale |
20.81 |
21,000 |
437,010 |
2,043,850 |
| ELMS STEVE | Director |
Jun 13 '25 |
Option Exercise |
3.43 |
332,680 |
1,140,763 |
420,010 |
| ELMS STEVE | Director |
Jun 16 '25 |
Sale |
20.24 |
194,749 |
3,941,720 |
87,330 |
| ELMS STEVE | Director |
Jun 13 '25 |
Sale |
20.82 |
137,931 |
2,871,723 |
282,079 |
| ELMS STEVE | Director |
Jun 12 '25 |
Sale |
21.69 |
92,941 |
2,015,890 |
2,031,730 |
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):